10 Supported by research
Severe vitamin D deficiency in infants can cause profound hypocalcemia resulting in afebrile convulsions.
"his serum calcium was 0.97. The normal range is 2.2 to 2.6 in that hospital, so alarmingly low. And then a few hours further to that, they came back and said, "And we now know the reason why: he was extremely deficient in vitamin D."" (said at 0:05:52)
Severe vitamin D deficiency is a well-established cause of profound symptomatic hypocalcemia in neonates and infants, commonly presenting as afebrile or metabolic seizures. In pediatric surveillance cohorts and clinical studies, infants with severe hypovitaminosis D frequently present with severe hypocalcemia and associated neuromuscular irritability, tetany, or seizures, which resolve upon treatment with calcium and vitamin D supplementation.
- supports: Nutritional rickets under 16 years: UK surveillance results. (Archives of disease in childhood 2020) · cited 56x in the literature
"Complications included delayed gross motor development (26.4%), fractures (9.6%), hypocalcaemic seizures (8%) and dilated cardiomyopathy (3%)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Vitamin D Deficiency Prevalence in Late Neonatal Hypocalcemia: A Multicenter Study. (Journal of clinical research in pediatric endocrinology 2021) · cited 2x in the literature
"Late neonatal hypocalcemia (LNH) is a common metabolic problem associated with hypoparathyroidism, high phosphate intake and vitamin D deficiency, often presenting with seizures." (abstract, introduction, passage verified)
pubmedfull study (doi) - supports: Severe Vitamin D Deficiency as a Trigger for Metabolic Seizures in Infancy: A Case Series … (Nutrients 2026)
"Hypocalcemia represents a major cause of seizures in children in the absence of fever or infections. Hypovitaminosis D, usually associated with a lack of proper prophylactic regimens, can trigger those events." (abstract, introduction, passage verified)
pubmedfull study (doi)
Gut bacteria ferment dietary fiber to produce short-chain fatty acids, which signal to the brain through the vagus nerve and the bloodstream.
"the fiber that we eat, those gut bugs will eat, they'll make short-chain fatty acids. And those short-chain fatty acids can almost switch a light on in your brain by sort of connecting with the vagus nerve, or they can go around in the bloodstream and get to the brain." (said at 0:24:05)
Gut bacteria ferment non-digestible dietary fiber into short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate. These metabolites communicate with the central nervous system through multiple established pathways, including direct activation of receptors (such as FFAR3) on vagal sensory neurons innervating the gastrointestinal tract, as well as entering the systemic circulation and crossing the blood-brain barrier to modulate neurophysiology and behavior.
- supports: Vagal neuron expression of the microbiota-derived metabolite receptor, free fatty acid rec… (Molecular metabolism 2021) · cited 105x in the literature
"Short-chain fatty acids (SCFAs) produced via gut microbiota fermentation of dietary fiber have been proposed to regulate host metabolism and feeding behavior via the vagus nerve, but the molecular mechanisms have not yet been elucidated... SCFA, particularly propionate, signaling occurs via free fatty acid receptor 3 (FFAR3), that we found expressed in vagal sensory neurons innervating throughout the gut." (abstract, background and results, passage verified)
pubmedfull study (doi) - supports: Short chain fatty acids: Microbial metabolites for gut-brain axis signalling. (Molecular and cellular endocrinology 2022) · cited 684x in the literature
"A key focus in this regard have been the short-chain fatty acids (SCFAs) produced by bacterial fermentation of dietary fibre, which include butyrate, acetate, and propionate. Ongoing research is focused on the entry of SCFAs into systemic circulation from the gut lumen, their migration to cerebral circulation and across the blood brain barrier, and their potential to exert acute and chronic effects on brain structure and function." (abstract, passage verified)
pubmedfull study (doi) - supports: Short-chain fatty acids in mood and schizophrenia spectrum disorders: Evidence in the fiel… (Progress in neuro-psychopharmacology & biological psychiatry 2025) · cited 1x in the literature
"The communication within MGBA involves various pathways leading through the vagus nerve and the bloodstream mediators. The latter are represented by short-chain fatty acids (SCFAs), produced by gut microbiota from dietary fiber." (abstract, passage verified)
pubmedfull study (doi)
According to US diagnostic thresholds, an HbA1c between 5.7% and 6.4% indicates prediabetes, and an HbA1c above 6.5% indicates type 2 diabetes.
"in the US, 5.7, I think to 6.4, is pre-diabetic, and above 6.5 is type 2 diabetes." (said at 0:25:28)
According to established US clinical diagnostic guidelines from the American Diabetes Association (ADA), an HbA1c level between 5.7% and 6.4% is classified as prediabetes (increased risk for diabetes), and an HbA1c of 6.5% or higher (≥6.5%) meets the diagnostic criterion for diabetes.
In a clinical trial by Dr. Sarah Hallberg testing a ketogenic diet for type 2 diabetes, 96% of participants reduced or discontinued insulin, 100% discontinued sulfonylureas, and average weight loss was 14% of body weight.
"Dr. Sarah Hallberg, who instituted a ketogenic diet in individuals with type 2 diabetes. And just to recap, 96% of these individuals were able to discontinue or reduce their insulin, and 100% were able to stop their sulfonylurea-class drugs. Average weight loss was 14% of body weight." (said at 0:27:47)
The speaker accurately recounts the findings of the 1-year clinical trial led by Dr. Sarah Hallberg evaluating a continuous remote care intervention utilizing nutritional ketosis (a ketogenic diet) for type 2 diabetes (PMID: 29417495). In that open-label, non-randomized controlled study of 262 intervention participants, sulfonylurea use was 100% eliminated, insulin was reduced or eliminated in 94% of users (very close to the spoken 96%), and mean weight loss was 13.8 kg (approximately 12% in the intention-to-treat cohort and up to ~14% among completers). Because the trial was non-randomized and open-label, the GRADE certainty of the evidence is low.
The acute stress response raises cortisol and adrenaline levels, which suppresses digestion and increases blood glucose levels.
"We need our cortisol levels to go up. We need our adrenaline levels to go up. And in that moment, we can run faster, you know, our brain thinks sharper, we switch off digestion, we pour sugar into our bloodstream to help us do all these things." (said at 0:16:28)
Published human physiological studies confirm that acute stress activates the sympathetic nervous system and hypothalamic-pituitary-adrenal (HPA) axis, leading to rapid surges in adrenaline (epinephrine) and cortisol. These hormonal elevations stimulate hepatic glucose production (via glycogenolysis and gluconeogenesis) and decrease peripheral glucose disposal, resulting in acute hyperglycemia to mobilize energy.
Localized intestinal inflammation triggers the release of systemic cytokines that transmit inflammatory signals to other organ systems throughout the body.
"when there's inflammation in the gut, lots of immune messengers that we call cytokines get triggered off and they take that message of inflammation and they send it to different organ systems." (said at 0:22:54)
The claim is supported by extensive biomedical research on inflammatory bowel disease (IBD) and intestinal barrier dysfunction. Intestinal inflammation leads to mucosal barrier disruption, microbial translocation, and local immune cell activation, which triggers the systemic release of inflammatory cytokines (such as IL-6, TNF-alpha, and IL-1beta) into the bloodstream. These circulating cytokines act as immune messengers to propagate inflammatory signals to extraintestinal organ systems, including the lungs, liver, kidneys, joints, skin, eyes, and central nervous system.
- supports: IL-6 Drives Neutrophil-Mediated Pulmonary Inflammation Associated with Bacteremia in Murin… (The American journal of pathology 2018) · cited 65x in the literature
"We further identified IL-6 as a systemic mediator of neutrophil recruitment from the bone marrow of dextran sulfate sodium animals. Functional inhibition of IL-6 led to reduced systemic and pulmonary neutrophilia, but it did not attenuate established colitis pathology. These data suggest that systemic bacteremia and pyrexia drive IL-6 secretion, which is a critical driver for pulmonary manifestation of IBD." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Genetic Deletion of LRP5 and LRP6 in Macrophages Exacerbates Colitis-Associated Systemic I… (Journal of immunology (Baltimore, Md. : 1950) 2022) · cited 9x in the literature
"Extraintestinal manifestations are common in inflammatory bowel disease and involve several organs, including the kidney... Furthermore, our studies show that aggravated colitis-associated systemic inflammation and AKI observed in LRP5/6 LysM mice are due to increased bacterial translocation to extraintestinal sites and microbiota-dependent increased proinflammatory cytokine levels in the kidney." (abstract, results)
pubmedfull study (doi) - supports: Deciphering the TLR4 and NLRP3 Inflammasome Crosstalk for Therapeutic Restoration of Intes… (Digestive diseases and sciences 2026) · cited 5x in the literature
"Dysregulation disrupts these protective mechanisms and initiates feed-forward cycle of epithelial damage, metabolic endotoxemia, dysbiosis, and heightened cytokine-driven inflammation. Such aberrant activity contributes to major intestinal diseases-including inflammatory bowel disease, necrotizing enterocolitis, and colorectal cancer-as well as extraintestinal conditions such as obesity, type 2 diabetes, and neuroinflammation through gut-brain axis pathways." (abstract, results, passage verified)
pubmedfull study (doi)
The February 2017 SMILES randomized controlled trial in Australia showed that patients with moderate to severe depression who followed a modified Mediterranean diet for 12 weeks achieved a statistically significant improvement in remission compared to those in a social support group.
"including that SMILES trial—did you see that from February 2017 in Australia?—that randomized controlled trial showing that patients with moderate to severe depression, the group who went on a modified Mediterranean diet versus the group who went on, I think, a social support structure for 12 weeks, had a statistically significant improvement in their remission." (said at 0:31:32)
The SMILES trial (Jacka et al., published in BMC Medicine in early 2017) was a 12-week, single-blind, randomized controlled trial conducted in Australia evaluating an adjunctive modified Mediterranean dietary intervention versus a social support control in 67 adults with moderate to severe depression. At 12 weeks, participants in the dietary intervention group achieved a statistically significant higher rate of remission (MADRS score <10) compared to the social support control group (32.3% vs. 8.0%, p = 0.028, NNT = 4.1).
- supports: A randomised controlled trial of dietary improvement for adults with major depression (the… (BMC medicine 2017) · cited 1080x in the literature
"'SMILES' was a 12-week, parallel-group, single blind, randomised controlled trial of an adjunctive dietary intervention in the treatment of moderate to severe depression. The intervention consisted of seven individual nutritional consulting sessions delivered by a clinical dietician. The control condition comprised a social support protocol to the same visit schedule and length... Remission, defined as a MADRS score <10, was achieved for 32.3% (n = 10) and 8.0% (n = 2) of the intervention and control groups, respectively (χ 2 (1) = 4.84, p = 0.028); number needed to treat (NNT) based on remission scores was 4.1 (95% CI of NNT 2.3-27.8)." (abstract, methods and results, passage verified)
pubmedfull study (doi)
Mechanistic research demonstrates that LPS may be a primary trigger in the development of insulin resistance and type 2 diabetes.
"And even something like type 2 diabetes, there's some really good mechanistic work that shows that LPS might be triggering—one of the root triggers in the development of insulin resistance, which then leads to type 2 diabetes." (said at 0:33:58)
The speaker accurately characterizes published mechanistic and preclinical research. Seminal animal studies (such as Cani et al., 2007) demonstrated that chronic subcutaneous infusion of lipopolysaccharide (LPS)—a state termed 'metabolic endotoxemia'—triggers low-grade systemic inflammation, hepatic insulin resistance, fasting hyperglycemia, and weight gain, mirroring diet-induced metabolic dysfunction. In human observational and clinical studies, elevated circulating LPS levels (metabolic endotoxemia) are consistently associated with insulin resistance and type 2 diabetes.
- supports: Metabolic endotoxemia initiates obesity and insulin resistance. (Diabetes 2007) · cited 6572x in the literature
"Seeking an inflammatory factor causative of the onset of insulin resistance, obesity, and diabetes, we have identified bacterial lipopolysaccharide (LPS) as a triggering factor... When metabolic endotoxemia was induced for 4 weeks in mice through continuous subcutaneous infusion of LPS, fasted glycemia and insulinemia and whole-body, liver, and adipose tissue weight gain were increased to a similar extent as in high-fat-fed mice." (abstract, results)
pubmedfull study (doi) - supports: Metabolic endotoxemia and diabetes mellitus: A systematic review. (Metabolism: clinical and experimental 2017) · cited 338x in the literature
"Most of the studies observed higher LPS or LBP concentrations in diabetic subjects than in healthy controls. T1DM and T2DM subjects presented higher mean fasting LPS of 235.7% and 66.4% compared with non-diabetic subjects, respectively." (abstract, results, passage verified)
pubmedfull study (doi)
LPS is the outer covering of gram-negative bacteria that reside in the gut and is an initiator of inflammation.
"LPS is something in the gut; it actually is the covering over certain bacteria called gram-negative bacteria that live in the gut. So we shouldn't really find it in the bloodstream. When we find it in the bloodstream, it got there somehow, and it means the gut is leaky. LPS is a powerful initiator of inflammation." (said at 0:34:28)
The speaker's statement accurately describes standard microbiological and immunological science. Lipopolysaccharide (LPS, also known as endotoxin) is the principal component of the outer membrane (covering) of Gram-negative bacteria residing in the intestinal tract. Under normal physiological conditions, the gut epithelial barrier restricts LPS translocation into systemic circulation. When intestinal barrier integrity is compromised (increased intestinal permeability or 'leaky gut'), LPS translocates into the bloodstream, where it binds Toll-like receptor 4 (TLR4) complexes and serves as a potent trigger of systemic inflammatory signaling.
- supports: Lipopolysaccharides derived from gram-negative bacterial pool of human gut microbiota prom… (International reviews of immunology 2022) · cited 65x in the literature
"Lipopolysaccharide (LPS) is the major component of the outer membrane of Gram-negative bacteria. It is found from intestinal microbes in the circulatory system and considered a trigger factor for low-grade inflammation in obesity. High-fat diet intake and its related obesity can cause gut microbiota disorder, leading to increased gut permeability, paracellular absorption and transcellular transport of endogenous endotoxin in the cardiovascular system." (abstract, background, passage verified)
pubmedfull study (doi) - supports: The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation. (Chronic stress (Thousand Oaks, Calif.) 2022) · cited 300x in the literature
"Lipopolysaccharide (LPS) is the main structural component of the outer membrane of most Gram-negative bacteria and has diverse immunostimulatory and procoagulant effects." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Gut barrier dysfunction and endotoxemia in heart failure: A dangerous connubium? (American heart journal 2023) · cited 29x in the literature
"Indeed, increased blood levels of lipopolysaccharide (LPS), a glycolipid of outer membrane of gut gram-negative bacteria, have been detected in patients with diabetes, obesity and nonalcoholic fatty liver disease or in patients with established coronary disease such as myocardial infarction or atrial fibrillation, suggesting endotoxemia as aggravating factor via systemic inflammation and eventually vascular damage. Upon interaction with its receptor Toll-like receptor 4 (TLR4) LPS may, in fact, act at different cellular levels so eliciting formation of proinflammatory cytokines or exerting a procoagulant activity." (abstract, background, passage verified)
pubmedfull study (doi)
Traditional Okinawan communities consumed an 80% carbohydrate diet while having low rates of type 2 diabetes, insulin resistance, and Alzheimer's disease.
"and we look at those Okinawan communities where they're having, you know, an 80% high-carbohydrate diet, and it's sort of kind of trying to figure out, "Well, how can that be, that they could have such a high-carb diet, certainly from the research I've read, yet not get type 2 diabetes, not have insulin resistance, not to have Alzheimer's?"" (said at 0:43:23)
Historical nutritional surveys of traditional Okinawan cohorts (such as the 1949 post-war nutritional data documented in the Okinawa Centenarian Study) show that the traditional Okinawan diet derived approximately 80% to 85% of total caloric energy from unrefined carbohydrates, predominantly orange-yellow sweet potatoes, with very low fat (~6%) and moderate-to-low protein intake. Despite this high-carbohydrate intake, these populations maintained a low overall glycemic load, caloric restriction, and exceptionally low rates of age-associated metabolic and neurodegenerative conditions, including type 2 diabetes, cardiovascular disease, and dementia, along with remarkable longevity. Certainty is graded as low due to reliance on observational, historical survey, and ecological cohort data.
- supports: The Okinawan diet: health implications of a low-calorie, nutrient-dense, antioxidant-rich … (Journal of the American College of Nutrition 2009) · cited 309x in the literature
"A comparison of the nutrient profiles of the three dietary patterns shows that the traditional Okinawan diet is the lowest in fat intake, particularly in terms of saturated fat, and highest in carbohydrate intake, in keeping with the very high intake of antioxidant-rich yet calorie-poor orange-yellow root vegetables, such as sweet potatoes, and green leafy vegetables." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Healthy aging diets other than the Mediterranean: a focus on the Okinawan diet. (Mechanisms of ageing and development 2014) · cited 265x in the literature
"The traditional diet in Okinawa is anchored by root vegetables (principally sweet potatoes), green and yellow vegetables, soybean-based foods, and medicinal plants... Overall, the important shared features of these healthy dietary patterns include: high intake of unrefined carbohydrates, moderate protein intake with emphasis on vegetables/legumes, fish, and lean meats as sources, and a healthy fat profile... This may reduce risk for chronic age-associated diseases and promote healthy aging and longevity." (abstract, results)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.